A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth.

AhR AhRR C/EBPβ TCDD carcinogenicity cyclooxygenase 2 inflammation interleukin 1 lymphoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 Apr 2019
Historique:
received: 28 03 2019
revised: 19 04 2019
accepted: 25 04 2019
entrez: 1 5 2019
pubmed: 1 5 2019
medline: 1 5 2019
Statut: epublish

Résumé

The aryl hydrocarbon receptor (AhR) is known for mediating the toxicity of environmental pollutants such as dioxins and numerous dioxin-like compounds, and is associated with the promotion of various malignancies, including lymphoma. The aryl hydrocarbon receptor repressor (AhRR), a ligand-independent, transcriptionally inactive AhR-like protein is known to repress AhR signaling through its ability to compete with the AhR for dimerization with the AhR nuclear translocator (ARNT). While AhRR effectively blocks AhR signaling, several aspects of the mechanism of AhRR's functions are poorly understood, including suppression of inflammatory responses and its putative role as a tumor suppressor. In a transgenic mouse that overexpresses AhRR (AhRR Tg) we discovered that these mice suppress 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)- and inflammation-induced tumor growth after subcutaneous challenge of EL4 lymphoma cells. Using mouse embryonic fibroblasts (MEF) we found that AhRR overexpression suppresses the AhR-mediated anti-apoptotic response. The AhRR-mediated inhibition of apoptotic resistance was associated with a suppressed expression of interleukin (IL)-1β and cyclooxygenase (COX)-2, which was dependent on activation of protein kinase A (PKA) and the CAAT-enhancer-binding protein beta (C/EBPβ). These results provide mechanistic insights into the role of the AhRR to suppress inflammation and highlight the AhRR as a potential therapeutic target to suppress tumor growth.

Identifiants

pubmed: 31035533
pii: cancers11050589
doi: 10.3390/cancers11050589
pmc: PMC6563059
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIEHS NIH HHS
ID : R01 ES019898
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES030419
Pays : United States
Organisme : University of California Cancer Center Cancer Immunology
ID : 48649
Organisme : NIEHS NIH HHS
ID : P30 ES023513
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30-ES023513
Pays : United States

Références

Food Addit Contam. 2000 Apr;17(4):289-302
pubmed: 10912243
J Biol Chem. 2001 Mar 23;276(12):9016-27
pubmed: 11114305
Carcinogenesis. 2000 Dec;21(12):2267-74
pubmed: 11133817
Clin Cancer Res. 2001 Oct;7(10):2998-3005
pubmed: 11595687
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9990-5
pubmed: 12107286
Oncogene. 2003 Feb 13;22(6):869-83
pubmed: 12584567
J Biol Chem. 1992 Mar 5;267(7):4338-44
pubmed: 1339449
Eur J Pharmacol. 1992 Mar 31;213(3):331-6
pubmed: 1377630
Biochem Pharmacol. 2003 Oct 1;66(7):1231-44
pubmed: 14505802
Leuk Res. 2004 Feb;28(2):179-90
pubmed: 14654083
J Biol Chem. 2004 Mar 5;279(10):8886-94
pubmed: 14684744
Mol Cell Biol. 2004 Apr;24(8):3238-50
pubmed: 15060147
J Biol Chem. 2005 Feb 11;280(6):4279-88
pubmed: 15561713
Mol Pharmacol. 2005 May;67(5):1393-8
pubmed: 15722456
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9218-23
pubmed: 15972329
Am J Pathol. 2005 Dec;167(6):1599-607
pubmed: 16314473
Biol Chem. 2006 Sep;387(9):1175-87
pubmed: 16972784
Cancer Res. 2007 Feb 1;67(3):1062-71
pubmed: 17283139
Cancer Res. 2007 Feb 15;67(4):1867-76
pubmed: 17308129
Am J Pathol. 2007 Nov;171(5):1538-48
pubmed: 17823287
Mol Endocrinol. 2007 Dec;21(12):2941-55
pubmed: 17823304
Cancer Res. 2007 Oct 1;67(19):9380-8
pubmed: 17909047
Mol Pharmacol. 2008 Feb;73(2):387-98
pubmed: 18000031
J Clin Invest. 2008 Feb;118(2):640-50
pubmed: 18172554
Biochem Pharmacol. 2009 Feb 15;77(4):485-97
pubmed: 18848529
Toxicol Appl Pharmacol. 2008 Dec 15;233(3):454-8
pubmed: 18848954
Cancer Cell. 2008 Nov 4;14(5):408-19
pubmed: 18977329
J Nutr. 2009 Jan;139(1):26-32
pubmed: 19056653
Science. 2009 Jan 9;323(5911):251-5
pubmed: 19131627
Science. 1991 Oct 18;254(5030):415-8
pubmed: 1925598
BMC Cancer. 2009 Jul 15;9:234
pubmed: 19604390
Methods Mol Biol. 2010;598:143-55
pubmed: 19967511
Nat Rev Cancer. 2010 Mar;10(3):181-93
pubmed: 20168319
Arch Biochem Biophys. 2011 Aug 1;512(1):78-86
pubmed: 21640702
Nature. 2011 Oct 05;478(7368):197-203
pubmed: 21976023
J Invest Dermatol. 2013 Jan;133(1):87-96
pubmed: 22951721
Nat Immunol. 2012 Dec;13(12):1162-70
pubmed: 23086447
Science. 2013 Jan 18;339(6117):286-91
pubmed: 23329041
Toxicol Sci. 2013 Jun;133(2):197-208
pubmed: 23492812
Toxicol Sci. 2014 Jul;140(1):135-43
pubmed: 24718703
Environ Health Perspect. 2015 Feb;123(2):193-9
pubmed: 25325234
Front Immunol. 2014 Nov 17;5:553
pubmed: 25452754
Carcinogenesis. 2015 Jun;36 Suppl 1:S232-53
pubmed: 26106141
JAMA Oncol. 2015 Nov;1(8):1061-8
pubmed: 26335650
Environ Health Perspect. 2016 Jul;124(7):1071-83
pubmed: 26862745
Oncotarget. 2016 Mar 8;7(10):10710-22
pubmed: 26909609
Sci Rep. 2016 May 17;6:26091
pubmed: 27184933
Sci Rep. 2016 Nov 29;6:38012
pubmed: 27897234
Arch Toxicol. 2018 Jan;92(1):225-240
pubmed: 28681081
J Biol Chem. 2017 Oct 27;292(43):17609-17616
pubmed: 28904176
Curr Opin Toxicol. 2017 Feb;2:109-119
pubmed: 28971163
Cancer Res. 1980 Oct;40(10):3616-20
pubmed: 6108157
Genes Dev. 1999 Jan 1;13(1):20-5
pubmed: 9887096

Auteurs

Christoph F A Vogel (CFA)

Department of Environmental Toxicology, University of California, One Shields Avenue, Davis, CA 95616, USA. cfvogel@ucdavis.edu.
Center for Health and the Environment, University of California, One Shields Avenue, Davis, CA 95616, USA. cfvogel@ucdavis.edu.

Yasuhiro Ishihara (Y)

Center for Health and the Environment, University of California, One Shields Avenue, Davis, CA 95616, USA. yaishihara@ucdavis.edu.
Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima 739-8521, Japan. yaishihara@ucdavis.edu.

Claire E Campbell (CE)

Center for Health and the Environment, University of California, One Shields Avenue, Davis, CA 95616, USA. cecampbell@ucdavis.edu.

Sarah Y Kado (SY)

Center for Health and the Environment, University of California, One Shields Avenue, Davis, CA 95616, USA. sykado@ucdavis.edu.

Aimy Nguyen-Chi (A)

Center for Health and the Environment, University of California, One Shields Avenue, Davis, CA 95616, USA. aimy.nguyenchi@gmail.com.

Colleen Sweeney (C)

Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA. casweeney@ucdavis.edu.

Marius Pollet (M)

Center for Health and the Environment, University of California, One Shields Avenue, Davis, CA 95616, USA. mpollet@ucdavis.edu.
Leibniz Research Institute for Environmental Medicine, 40225 Düsseldorf, Germany. mpollet@ucdavis.edu.

Thomas Haarmann-Stemmann (T)

Leibniz Research Institute for Environmental Medicine, 40225 Düsseldorf, Germany. haarmann@uni-duesseldorf.de.

Joseph M Tuscano (JM)

Division of Hematology & Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA. jtuscano@UCDAVIS.EDU.

Classifications MeSH